Cargando…
Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib and gefitinib have shown promising efficacy and tolerability in patients with advanced NSCLC. Identifying subgroups of patients who benefit from EGFR-TKI treatment may help achieve better treatment...
Autores principales: | Shahriari, Saeedeh, Seifi, Sharareh, Khodakarim, Nastaran, Ramim, Tayeb, Dashtpeima, Alireza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iran University of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448506/ https://www.ncbi.nlm.nih.gov/pubmed/36128277 http://dx.doi.org/10.47176/mjiri.36.31 |
Ejemplares similares
-
Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer
por: Komaki, Ritsuko, et al.
Publicado: (2015) -
Relationship between weight gain and survival rate in patients with metastatic lung cancer
por: Fardad, Farshid, et al.
Publicado: (2021) -
Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014) -
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018) -
Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer
por: Varkaris, Andreas, et al.
Publicado: (2019)